Drug Profile
IRX 4310
Alternative Names: AGN-194310; AGN-4310; ALRT-4310; LGD-4310; NRX-4310Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Allergan; Ligand Pharmaceuticals
- Developer Allergan; Io Therapeutics
- Class Antipsoriatics; Benzoic acids; Thiophenes
- Mechanism of Action Retinoic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neutropenia
- Discontinued Acne; Atopic dermatitis; Psoriasis; Xerostomia
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 19 Apr 2016 No recent reports on development identified - Preclinical for Neutropenia (Chemotherapy-induced) in USA (PO)
- 06 Oct 2011 Discontinued - Phase-II for Acne in United Kingdom (unspecified route)